Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders

Drugs and Aging

Volumn 10, Issue 4, 1997, Pages 299-322

  Davis, Rick ^a   Faulds, Diana ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; GENERAL SURGERY; HEALTH CARE COST; HEMATOMA; HOME CARE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; MOLECULAR WEIGHT; NONHUMAN; ORAL DRUG ADMINISTRATION; ORTHOPEDIC SURGERY; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS;

EID: 0030972039     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199710040-00006     Document Type: Review

References (110)

1. Barradell LB, Buckley MM. Nadroparin calcium: a review of its pharmacology and clinical applications in the prevention and treatment of thromboemholic disorders. Drugs 1992 Nov: 44: 858-88
2. Fareed J, Walenga JM, Williamson K, et al. Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments. Semin Thromb Hemost 1985; 11 (1): 56-74
3. Hirsh J. Heparin and low-molecular weight heparins. Coron Artery Dis 1992 Nov; 3: 990-1002
4. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17
5. Colman RW, Scott CF, Pixley RA, et al. Effect of heparin on the inhibition of contact system enzymes. Ann N Y Acad Sci 1989; 556: 95-103
6. Wolf H. Low molecular weight heparin. Med Clin North Am 1994; 78: 733-43
7. Nielsen JI, Ostergard P. Chemistry of heparin and low molecular weight heparin. Acta Chir Scand 1988; 543 Suppl.: 52-6
8. Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 1990; 40 (4): 498-530
9. Laurent TC, Tengblad A, Thunberg L, et al. The molecular-weight-dependence of the anti-coagulant activity of heparin. Biochem J 1992; 175: 691-701
10. Griffith MJ. Kinetics of the heparin-enhanced antithrombin II/ thrombin reaction: evidence for a template model for the mechanism of action of heparin. J Biol Chem 1982; 257: 7360-5
11. Thunherg L, Lindahl U, Tengblad A, et al. On the molecular-weight-dependence of the anticoagulant activity of heparin. Biochem J 1979; 181: 241-3
12. Andersson L-O, Barrowcliffe TW, Holmer H, et al. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effects of heparin neutralization in plasma. Thromb Res 1979; 15: 531-41
13. Denton J, Lane DA, Thunberg L, et al. Binding of platelet factor 4 to heparin oligosaccharides. Biochem J 1983; 209: 455-60
14. Schoen P, Lindhout T, Franssen J, et al. Low molecular weight heparin-catalyzed inactivation of factor Xa and thrombin by antithrombin III - effect of platelet factor 4. Thromb Haemost 1991 Oct 1; 66: 435-41
15. Barrowcliffe TW, Curtis AD, Johnson EA, et al. An international standard for low molecular weight heparin. Thromb Haemost 1988; 60: 1-7
16. Padilla A, Gray E, Pepper DS, et al. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4). Br J Haematol 1992 Oct; 82: 406-13
17. Schoen P, Lindhout T, Hemker HC. Ratios of anti-factor Xa to antithrombin activities of heparins as determined in recalcified human plasma. Br J Haematol 1992 Jun; 81: 255-62
18. Fareed J, Walenga JM, Racanelli A, et al. Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins. Haemostasis 1988; 18 Suppl. 3: 33-47
19. Hemker HC. A standard for low molecular weight heparin? [editorial]. Haemostasis 1989; 1: 1-4
20. Fareed J, Jeske W, Hoppensteadt D. Are the available low-molecular-weight heparin preparations the same? Semin Thromb Hemost 1996; 22 Suppl. 1: 77-91
21. ® technical brochure. Sanofi Pharma, France, 1995.
22. Hirsh J, Barrowclilfe TW. Standardization and clinical use of LMW heparin. Thromb Haemost 1988; 59: 233
23. 2+ ions: why the anti-Xa activity of LMW heparins is about two times overestimaled [letter]. Thromb Haemost 1993; 70 (4): 717-8
24. Béguin S, Wielders S, Lormeau JC, et al. The mode of action of CY216 and CY222 in plasma. Thromb Haemost 1992 Jan; 67: 33-41
25. Choay J, Petitou M, Lormeau JC, et al. Structure activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116: 492-9
26. Béguin S, Choay J, Hemker HC. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemost 1989; 61 (3): 374-401
27. Hemker HC, Béguin S, Kakkar VV. Can the haemorrhagic component of heparin be identified? Or an attempt at clean thinking on a dirty drug. Haemostasis 1996; 26 (3): 117-26
28. Berrettini M, Parise P, Malaspina M, et al. Effect of standard heparin and low M.W heparin (CY 216) on plasma levels of tissue factor pathway inhibitor [abstract no. C 013]. Thromb Res 1993; 70 Suppl. 1: 15
29. Hoppensteadt DA, Jeske W, Fareed J, et al. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul Fibrinolysis 1995 Jun; 6 Suppl. 1: S57-64
30. Gaffney PJ, March NA, Thomas DP. The influence of heparin and heparin like substances on the fibrinolytic system in vivo. Haemostasia 1982; 12: 85
31. Stassen JM, Juhan-Vague I, Alessi MC, et al. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator. Thromb Haemost 1987; 58: 947-50
32. Vairel EG, Brouty-Boye H, Toulemonde F, et al. Heparin and a low molecular weight fraction enhance thrombolysis and by this pathway exercise a protective effect against thrombosis. Thromb Res 1983; 30: 219-24
33. Fareed W, Walenga JM, Hoppensteadt DA, et al. Studies on the protibrinolytic actions of heparin and its fractions. Semin Thromb Hemost 1985; 11: 199-207
34. Pogliani EM, Salvatore M, Baragetti I, et al. Effect of a low-molecular-weight heparin, calcium nadroparine (CY216), on fibrinolysis in patients undergoing surgery. Curr Ther Res 1993 Feb; 53: 180-7
35. Parise P, Ascani A, Morini M, et al. Effect of unfractionated heparin (UH) and a LMWH (CY 216) on fibrinolysis in vivo [abstract]. Thromb Res 1993; 70 Suppl. 1: 18
36. Boisseau MR, Freyburger G, Dachary J, et al. Effects of CY 216 and standard heparin on hemorheological factors. In: Bounameaux H, Samama M, ten Cate JW, editors. Proceedings of the Second International Symposium on Fraxaparin. Stuttgart: Schattauer, 1990: 125-32
37. ®) in an experimental model of human venous thrombosis. Thromb Haemost 1995 Nov; 74: 1286-92
38. Collignon F, Frydman A, Caplain H, et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995 Apr; 73: 630-40
39. Rostin M, Montastruc JL, Houin G, et al. Pharmacodynamics of CY 216 in healthy volunteers inter-individual variations. Fundam Clin Pharmacol 1990; 4 (1): 17-23
40. Harenberg J, Wurzner B, Zimmermann R, et al. Bioavailability and antagonization of the low molecular weight heparin CY 216 in man. Thromb Res 1986 Nov 15; 44: 549-54
41. Freedman MD, Leese P, Prasad R, et al. An evaluation of the biological response to fraxiparine, (a low molecular weight heparin) in the healthy individual. J Clin Pharmacol 1990 Aug; 30: 720-7
42. Agnelli G, Iorio A, Renga C, et al. Prolonged antithrombin activity of low-molecular-weight heparins: clinical implications for the treatment of thromboembolic diseases. Circulation 1995 Nov 15; 92: 2819-24
43. Hoppensteadt D, Walenga JM, Fareed J. Low molecular weight heparins: an objective overview. Drugs Aging 1992; 2 (5): 406-22
44. Cziraky MJ, Spinler SA. Low-molecular-weight heparins for the treatment of deep-vein thrombosis. Clin Pharm 1993 Dec; 12: 892-9
45. Bara L, Billaud E, Gramond G, et al. Comparative pharmacokinetics of low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985; 39: 631-6
46. Frydman A, Bara L, Feroux Y, et al. The antithrombic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin, in man given single subcutaneous doses of 20 up to 80mg. J Clin Pharmacol 1988; 28: 609-18
47. Lutomski DM, Bottorff M, Sangha K. Pharmacokinetic optimisation of the treatment of embolic disorders. Clin Pharmacokinet 1995; 28 (1): 67-92
48. Kandrolas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1992; 22 (5): 359-74
49. ®) in various stages of chronic renal failure. Nephron 1991 Dec; 59: 543-5
50. Sanofi-Winthrop. Nadroparin calcium prescribing information. Gentilly, France, 1996.
51. Pineo GF, Hull RD. Prevention and treatment of venous thromboembolism. Drugs 1996; 52 (1): 71-92
52. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992 Sep 5; 305: 567-74
53. Nurmohamed MT, Büller HR, ten Cate JW. Physiological changes due to age: implications for the prevention and treatment of thrombosis in older patients. Drugs Aging 1994; 5 (1): 20-33
54. Nurmohamed MT, Rosendaal FR, Büller HR, et al. Low molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992 Jul 18; 340: 152-6
55. Leiorovicz A, Haugh MC, Chapuis F-R, et al. Low molecular weight heparin in the prevention of perioperative thrombosis. BMJ 1992 Oct 17; 305: 913-20
56. European Fraxiparin Study (EFS) Group. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg 1988 Nov; 75: 1058-63
57. Kakkar VV, Murray WJ. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study. Br J Surg 1985 Oct; 72: 786-91
58. Bounameaux H, Huber O, Khabiri E, et al. Unexpectedly high rate of phlebographic deep venous thrombosis following elective general abdominal surgery among patients given prophylaxis with low-molecular-weight heparin. Arch Surg 1993 Mar; 128: 326-8
59. ® (CY-216) for the prevention of postoperative deep vein thrombosis in patients undergoing general surgery under epidural anaesthesia [in French]. Ann Fr Anesth Reanim 1994; 13 (3): 311-7
60. Pezzuoli G, Neri-Serneri GG, Settembrini P, et al. Prophylaxis of fatal pulmonary embolism in general surgery using low-molecular weight heparin Cy 216: a multicentre, double-blind, randomized, controlled, clinical trial versus placebo (STEP). STEP-Study Group. Int Surg 1989 Oct-Dec; 74: 205-10
61. German Hip Arthroplasty Trial (GHAT) Group. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement: a randomized trial. Arch Orthop Trauma Surg 1992; 111: 110-20
62. Haentjens P. The Belgian Fraxiparine Study Group. Thromboembolic prophylaxis in orthopaedic trauma patients: a comparison between a fixed dose and individually adjusted dose of a low molecular weight heparin (nadroparin calcium). Injury 1996; 27 (6): 385-90
63. Hamulyák K, Lensing AWA, van der Meer J, et al. Subcutaneous low-molecular weight heparin or oral anticoagulants for prevention of deep-vein thrombosis in elective hip or knee replacement? Thromb Haemost 1994; 74 (6): 1428-31
64. Leyvraz PF, Bachmann F, Hoek J, et al. Prevention of deep vein thrombosis after hip replacement: randomised comparison hetween unfractionated heparin and low molecular weight heparin. BMJ 1991 Sep 7; 303: 543-8
65. Palareti G, Borghi B, Coccheri S, et al. Postoperative versus preoperative initiation of deep-vein thrombosis prophylaxis with a low-molecular-weight heparin (Nadroparin) in elective hip replacement. Clin Appl Thromb Hemost 1996; 2 (1): 18-24
66. Forette B, Wolmark Y. Tolerance to nadroparin calcium for the prevention of thromboembolism in the elderly [in French]. Presse Med 1995 Mar 25; 24: 567-71
67. Harenberg J, Roebruck P, Heene DL. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. Haemostasis 1996 May-Jun; 26: 127-39
68. Wicky J, Couson F, Ambrosetti P, et al. Postoperative deep venous thrombosis (DVT) and low-molecular-weight heparin (LMWH) type and dosage [letter]. Thromb Haemost 1993 Apr 1; 69: 402-3
69. Dorfman GS, Cronan JJ, Tupper TB. Occult pulmonary embolism: a common occurence in deep vein thrombosis. Am J Radiol 1987; 148: 263
70. Hull R, Hirsch J, Carter C, et al. Pulmonary angiography, ventilation lung scanning and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med 1983; 98: 891
71. Gibaldi M, Wittkowsky AK. Contemporary use of and future roles for heparin in antithrombotic therapy. J Clin Pharmacol 1995; 35 (11): 1031-45
72. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism: a statement for healthcare professionals. Circulation 1996 Jun 15; 93: 2212-45
73. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996 Mar 14; 334: 682-7
74. Ninet J, Bachet P, Prandoni P. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous un fractionated heparin in the treatment of deep vein thrombosis. A Collaborative European Multicentre Study. Thromb Haemost 1991 Mar 4; 65: 251-6
75. Prandoni P, Lensing AWA, Büller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992 Feb 22; 339: 441-5
76. Charbonnier BA, Fiessinger J-N, Sixma JJ, et al. Comparison of a once daily versus a twice daily subcutaneous nadroparin calcium regimens in the treatment of deep vein thrombosis. On behalf of the FRAXODI Group [abstract no. 4343]. Circulation 1996 Oct 15; 94 (8) Suppl.: 1-742
77. Théry C, Simonneau G, Meyer G, et al. Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study. Circulation 1992 Apr; 85: 1380-9
78. Marshall RS, Mohr JP. Current management of ischaemic stroke. J Neurol Neurosurg Psychiatry 1993; 56: 6-16
79. Adams Jr HP, Brott TG, Crowell RM, et al. Guidelines for the management of patients with acute ischaemic stroke: a statement for healthcare professionals from a special writing group of the Stroke Council. American Heart Association. Stroke 1994; 25: 1901-14
80. Bath PMW. Treating acute ischaemic stroke: still no effective drug treatment available. BMJ 1995 Jul 15; 311: 139-40
81. Kay R, Wong KS, Woo J. Pilot study of low-molecular-weight heparin in the treatment of acute ischemic stroke. Stroke 1994 Mar; 25: 684-5
82. Kay R, Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995 Dec 14; 333: 1588-93
83. Gurfinkel EP, Manos LJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995 Aug; 26: 313-8
84. Hauch O, Shrine C, Khattar MD, et al. Cost-benefit of prophylaxis against deep vein thrombosis in surgery. Semin Thromb Hemost 1991; 17 Suppl. 3: 280S-3S
85. Oster G, Tuden RL, Colditz GA. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. JAMA 1987; 257: 203-8
86. Bergqvist D, Matzsch T. Cost/benefit aspects on thrombopiophylaxis. Haemostasis 1993; 23 Suppl. 1: 15S-9S
87. Bergqvist D, Mätzsch T, Jendleg S, et al. The cost-effectiveness of prevention of post-operative thromboembolism. Acta Chir Scand 1990; 556 Suppl.: 36-41
88. Bergqvist D, Lindgren B, Mätzch T. Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin. Br J Surg 1996; 83: 1548-52
89. Borris LC, Lassen MR, Jensen HP, et al. Perioperative thrombosis prophylaxis with low molecular weight heparins in elective hip surgery: clinical and economic considerations. Int J Clin Pharmacol Ther 1994; 32 (5): 262-8
90. Heaton D, Pearce M. Low molecular weight versus unfractionated heparin: a clinical and economic appraisal. Pharmacoeconomics 1995 Aug; 8: 91-9
91. Levesque H, Cailleux N, Vasse D, et al. Cost evaluation of treatment of deep venous thromhosis (on sic days): comparison of subcutaneous nadroparin and intravenous heparin in 40 hospitalised patients [in French]. Therapie 1994 Mar-Apr; 49: 101-5
92. Schafer AI. Low-molecular-weight heparin-an opportunity for home treatment of venous thrombosis [editorial]. N Engl J Med 1996 Mar 14; 334: 724-5
93. Aster RH. Heparin-induced thrombocytopenia and thrombosis [letter]. N Engl J Med 1995; 332: 1374-6
94. Borris LC, Lassen MR. A comparative review of the adverse effect profiles of heparins and heparinoids. Drug Saf 1995; 12 (1): 26-31
95. Manito N, Alio J, Martinez BE. Thrombosis and thrombocytopenia associated with the use of unfractionated heparin in a patient with unstable angina [in Spanish]. Rev Clin Esp 1991 Oct; 189: 224-6
96. Laivre R, Petiteau P-Y, Kieffer Y. Low molecular weight heparin-induced thrombocytopenia complicated by massive pulmonary embolism and acute myocardial infarction: a case report. Thromb Haemost 1993 Jun 30; 69: 1117
97. Faivre R, Kieffer Y, Bassand JP, et al. Severe heparin-induced thromhocytopenia: value of low molecular weight heparin. Apropos of 6 cases [in French]. Arch Mal Coeur Vaiss 1985 Jan; 78: 27-30
98. Leroy J, Leclerc MH, Delahousse B, et al. Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216). Semin Thromb Hemost 1985 Jul; 11: 326-9
99. Gouault-Heilmann M, Huet Y, Adnot S, et al. Low molecular weight heparin as an alternative therapy in heparin-induced thrombocytopema. Haemostasis 1987; 17: 134-40
100. Luzzatto G, Cordiano I, Patrassi G, et al. Heparin-induced thromboeytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use [letter]. Thromb Haemost 1996 Jan; 75: 211-3
101. Vun CM, Evans S, Chong BH. Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia. Thromb Res 1996 Mar 1; 81: 525-32
102. Albanese C, Bellani M, Longatti S, et al. Comparison of the local tolerability of two subcutaneous low molecular weight heparins: CY 216 and enoxaparine. Curr Ther Res 1992 Mar; 51: 469-75
103. Billon N, Gloaguen F, Funck-Brentano C, et al. Clinical evaluation of pain during subcutanteous injections of low molecular weight heparins in healths volunteers. Br J Clin Pharmacol 1994 Apr; 37: 395-7
104. Hull RD, Pineo GF. Therapeutic use of low molecular weight heparins: knowledge to dale and their application to therapy. Semin Thromb Hemost 1994; 20 (4): 339-44
105. Weitz J. New anticoagulant strategies: current status and future potential. Drugs 1994; 48 (4): 485-97
106. Leizonnicz A, Simonneau G, Decousus H. Comparison of efficacy and safety of low molecular weight heparins and untractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994 Jul 30; 309: 299-304
107. Siragusa S, Cosmi B, Piovella F, et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a metaanalysis. Am J Med 1996 Mar; 100: 209-77
108. Lensing AWA, Prins MH, Davidson BL. Treatment of deep venous thrombosis with low-molecular-weight heparins: a metaanalysis. Arch Intern Med 1995 Mar 27; 155: 601-7
109. Bergqvist D. Review of clinical trials of low molecular weight heparins: clinical review. Eur J Surg Acta Chir 1992; 158 (2): 67-78
110. Dunn CJ, Goa KL. Enoxaparin: a pharmacoeconomic appraisal of its use in thromboprophylaxis after total hip arthroplasty. Pharmacoeconomics 1996; 10 (2): 179-90